Skip to main
AQST

AQST Stock Forecast & Price Target

AQST Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aquestive Therapeutics Inc is positioned favorably in the specialty pharmaceutical market, particularly due to its focus on the no-needle epinephrine sector, which showcases a promising growth opportunity for oral and intranasal alternatives. The company's stock experienced a significant uptick of 43.77% following the FDA's decision not to require an Advisory Committee meeting for the New Drug Application (NDA) of Anaphylm, indicating strong investor confidence in its regulatory progress. The successful preparation of the data package for the NDA suggests that Aquestive is on a solid path towards potential approval, bolstering expectations for revenue growth from its innovative product offerings.

Bears say

Aquestive Therapeutics is facing significant financial risks, primarily due to the potential failure of the development of AQST-109, which could hinder future growth. Additionally, there are concerns regarding an anticipated decline in revenues from its licensed commercial products, impacting the company's overall financial stability. The necessity to raise capital further complicates Aquestive's financial outlook, indicating weaknesses in its balance sheet that could affect investor confidence.

AQST has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aquestive Therapeutics Inc (AQST) Forecast

Analysts have given AQST a Buy based on their latest research and market trends.

According to 5 analysts, AQST has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aquestive Therapeutics Inc (AQST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.